Archive for January, 2012

Structure and Replication of Orthomyxoviruses

January 31, 2012 1 comment


Influenza A, B, and C viruses are the only members of the Orthomyxoviridae family, and only influenza A and B viruses cause significant human disease. The orthomyxoviruses are enveloped and have a segmented negative-sense RNA genome. The segmented genome of these viruses facilitates the development of new strains through the mutation and reassortment of the gene segments among different human and animal (influenza A) strains of virus. This genetic instability is responsible for the annual epidemics (mutation: drift) and periodic pandemics (reassortment: shift) of influenza infection worldwide.

Influenza is one of the most prevalent and significant viral infections. There are even descriptions of influenza epidemics (local dissemination) that occurred in ancient times. Probably the most famous influenza pandemic (worldwide) is the Spanish influenza that swept the world in 1918 to 1919, killing 20 to 40 million people. In fact, more people died of influenza during that time than in the battles of World War I. Pandemics caused by novel influenza viruses occurred in 1918, 1947, 1957, 1968, and 1977, but fortunately none have occurred since. New virus strains have been detected since the last pandemic, including an outbreak of avian influenza first noted in Hong Kong in 1997, which has caused some human disease and fatalities. Fortunately, prophylaxis in the form of vaccines and antiviral drugs is now available for people at risk for serious outcomes.

To read more click on this link to the full article: Structure and Replication of Orthomyxoviruses.

Are Viruses Alive?

January 13, 2012 4 comments

The question of whether viruses are living or not always provokes lively discussion. An informal poll of blog’s readers on this issue is located in the sidebar on the right side of the screen or available also for discussion here.

Categories: Virology

Scientists Characterize Protein Essential to Survival of Malaria Parasite

January 11, 2012 Leave a comment

A biology lab at Washington University has just cracked the structure and function of a protein that plays a key role in the life of a parasite that killed 655,000 people in 2010.

A cartoon based on the electron density map makes it easier to see the protein’s structure and figure out how it works. The enzyme’s job is to add a methyl group — three times — to a starting molecule as part of a process for making cell membranes. In this cartoon, the phosphate is a stand-in for the starting molecule and the green molecule is the one that donates a methyl group. Both are positioned in the active site of the enzyme, the pocket where the chemistry takes place. (Credit: Jez)

The protein is an enzyme that Plasmodium falciparum, the protozoan that causes the most lethal form of malaria, uses to make cell membrane.

The protozoan cannot survive without this enzyme, but even though the enzyme has many lookalikes in other organisms, people do not make it. Together these characteristics make the enzyme an ideal target for new antimalarial drugs.

The research was published in the January 6 issue of the Journal of Biological Chemistry (JBC) as “Paper of the Week” for that issue.

The work also will be featured in ASBMB Today (the newsletter of the American Society for Biological Molecular Biology, which publishes JBC).

Sweating the cold room

The protein’s structure might have remained an enigma, had it not been the “unreasonable optimism” of Joseph Jez, PhD, associate professor of biology in Arts & Sciences, which carried his team through a six-year-long obstacle course of failures and setbacks.

“What my lab does is crystallize proteins so that we can see what they look like in three dimensions,” Jez says. “The idea is that if we know a protein’s structure, it will be easier to design chemicals that would target the protein’s active site and shut it down,” Jez says.

The latest discovery is the culmination of a project that began years before when Jez was working at the Danforth Plant Science Center in St. Louis and collaborating with scientists at the local biotech startup Divergence. “At the time, C. elegans had just been sequenced and the Divergence scientists were looking at using it as an easy model to work out the biochemistry of parasitic nematodes,” Jez says.

C. elegans is a free-living nematode, or microscopic roundworm, but many nematodes are parasitic and cause disease in plants, livestock and people.

During this project, Lavanya Palavalli, a summer intern working with Jez, crystallized the C. elegans version of the enzyme. The job of the enzyme, phosphoethanolamine methyltransferase, thankfully abbreviated to PMT, is to add methyl groups to a starting molecule, phosophoethanolamine.

“When Soon Goo Lee later took up the project,” says Jez, “the plan was to try to grow better crystals of the C. elegans protein, ones good enough to get readable X-ray diffraction patterns.

Two years later, the crystals were looking better but still not good enough.

So Jez suggested that Lee go after homologous (look-alike) proteins in other organisms. “Even though the proteins are homologous, each has a different amino acid sequence and so will behave differently in the crystallizations,” Jez says. “Lee went from working with two C. elegans proteins to three plant proteins, two other nematode proteins and then the Plasmodium protein,” Jez says.

“He took all six of those PMT versions into the crystallization trials to maximize his odds,” Jez says.

“To crystallize a protein,” Jez says, “we put a solution of a salt or something else that might work as a desiccant in the bottom of a small well. And then we put a drop of our liquid protein on a microscope cover slip and flip it over the top of the well, so the drop of protein is hanging upside down in the well.”

“What we’re trying to do is to slowly withdraw water from the protein. It’s exactly like making rock candy, only in that case, the string hanging into the jar of sugar solution helps to withdraw water,” he says.

The difference is that sugar wants to form crystals and proteins are reluctant to do so.

“There are 24 wells to a tray, and we usually screen 500 wells per protein at first,” Jez says. “Lee had eight proteins and so his first pass was to screen 4,000 conditions. And then he had to try different combinations of ligands to the proteins and crystallize those. This is why it took a few years to finally get where he needed to go.”

Road trip!

 The scientists need crystals — preferably nice, big ones — to stick in the path of an X-ray beam at Argonne National Laboratory in Chicago. (If the crystal is a good one, and all the atoms are lined up in a repeating array, the scattered X-rays will produce a clear pattern of spots.)

Embedded in that pattern is the mathematical information needed to back-calculate to the position of the atoms in the protein, a process a bit like throwing a handful of pebbles in a lake and then calculating where they landed by the pattern of waves arriving at the shoreline.

Lee got the PMT from Haemonchus contortus to crystallize first, but there were technical issues with the diffraction pattern that would have made solving it technically and computationally very demanding.

“When the Plasmodium enzyme finally crystallized, Soon got four crystals kind of stacked on top of each other and each of them was paper thin,” Jez says.

“I never thought it would work, but we took them to Argonne anyway and he actually did surgery under the microscope and cracked off a little tiny piece of it.”

To everyone’s surprise, he got a clean diffraction pattern from the crystal. “Because the Plasmodium enzyme was the smallest one and the easiest to work on, we pushed that one first,” Jez says.

The moment of truth

“Once we had a Plasmodium crystal that was diffracting really well, we could try back-calculating to see whether we could extract the atom positions from the data,” Jez says.

After the computer finished its calculations, Lee clicked a mouse button to see the results, which would reveal whether his years of work finally would pay off.

When Lee clicked the mouse, he got an electron density map in exceptionally sharp focus.

“When you see a map like that, it’s like suddenly the wind has kicked up and you’re sailing free,” Jez says, “because there’s this moment, like, before you click that button, no one has ever seen how this protein is put together in three dimensions. You’re the first person to ever see it.

“The irony of it is we got such good quality diffraction pattern and electron density maps off such an ugly crystal,” he says.

Lock and load

“Once you have the electron density map, the task is to build a structure that matches the amino acid sequence of the protein,” Jez says.

“The first thing you do is put in the amino acid backbones and connect them together to form a chain. It’s like having a long thread, each inch of which is an amino acid, and your job is to take that thread and move it in three dimensions through that electron density map.”

The next step is to add the side chains that make one amino acid different from another, Jez says. “The amino acid sequence is known,” he says. “Your goal is to match the way you string together the amino acids in the electron density map to that sequence.”

“Once you have the overall structure, you can start to figure out how the enzyme works. The PMT enzyme is trying to join two molecules,” Jez says. “To do that, it has to lock them in place so that the chemistry can happen, and then it has to let go of them.

“We think the protein has a lid that opens and closes,” he says. “The active site stays open until the substrates enter, and then the lid clamps down, and when it clamps down it actually puts the substrates together.”

Calling Bill and Melinda Gates

Not only do infections by Plasmodium falciparum cause the most severe form of malaria, about 40 percent of the human population lives in areas where the parasite is endemic. Moreover, drugs that used to be effective against malaria are beginning to fail, in part because widespread drug counterfeiting has led to resistance.

New anti-malarial drugs are desperately needed, and the PMT protein is an ideal target. If PMT is disabled, the protozoan can’t make cell membranes and it dies. Moreover, a drug that would kill Plasmodium might have minimal side effects on patients.

Although the process of identifying compounds that would target PMT is in the early stages, a handful of anti-parasitical compounds used to treat diseases are known to block PMT as well.

As for Lee, he has had a hard go of it, but now things are breaking his way. Plasmodium PMT is giving up its secrets, and the plant and nematode PMTs are coming along as well.

When he clicked the mouse button and a clean electron density map came up, he says, it was like seeing “the light at the end of a five-year-long tunnel.”

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Washington University in St. Louis.

Journal Reference:

S. G. Lee, Y. Kim, T. D. Alpert, A. Nagata, J. M. Jez.Structure and Reaction Mechanism of Phosphoethanolamine Methyltransferase from the Malaria Parasite Plasmodium falciparum: AN ANTIPARASITIC DRUG TARGETJournal of Biological Chemistry, 2011; 287 (2): 1426 DOI:10.1074/jbc.M111.315267

How Dengue Infection Hits Harder the Second Time Around

One of the most vexing challenges in the battle against dengue virus, a mosquito-borne virus responsible for 50-100 million infections every year, is that getting infected once can put people at greater risk for a more severe infection down the road.

The cluster of dark dots near the center of this micrograph shows dengue virus particles. (Credit: CDC)

Now, for the first time, an international team of researchers that includes experts from the University of California, Berkeley, has pulled apart the mechanism behind changing dengue virus genetics and dynamics of host immunity, and they are reporting their findings in the Dec. 21 issue of Science Translational Medicine.

The virus that causes dengue disease is divided into four closely related serotypes (dengue virus 1, 2, 3 and 4), and those serotypes can be further divided into genetic variants, or subtypes.

The researchers showed that a person’s prior immune response to one serotype of dengue virus could influence the interaction with virus subtypes in a subsequent infection. How that interaction plays out could mean the difference between getting a mild fever and going into a fatal circulatory failure from dengue hemorrhagic fever or dengue shock syndrome.

The findings have implications for the efforts to combat a disease that has grown dramatically in recent decades, including the development of a first-ever dengue vaccine.

According to the World Health Organization, dengue disease is now endemic in more than 100 countries around the world, and recent estimates say some 3 billion people — almost half of the world’s population — are at risk.

It was already known that upon a person’s first infection with dengue virus, the immune system reacts normally by creating antibodies to fight the viral invaders. The problem is that those antibodies can then be confused if confronted later with one of the other three types of dengue virus, and as this new study revealed, even different subtypes within the same serotype.

“With the second infection, the antibodies sort of recognize the new type of viruses, but not well enough to clear them from the system,” said study lead author Molly OhAinle, post-doctoral fellow in infectious diseases at UC Berkeley’s School of Public Health. “Instead of neutralizing the viruses, the antibodies bind to them in a way that actually helps them invade the immune system’s other cells and spread.”

The study authors noted that this Trojan horse effect has been shown before, but the new research provides an analysis of the interplay between viral genetics and immune response with unprecedented detail, going beyond the main serotype.

Putting the puzzle pieces together required UC Berkeley’s expertise in immunology and virology, the genome analysis and biostatistical capabilities at the Broad Institute of Harvard University and Massachusetts Institute of Technology, and the epidemiological and clinical field work at Nicaragua’s National Virology Laboratory.

Researchers used data from two independent, Nicaragua-based studies headed by Eva Harris, professor of infectious diseases and vaccinology and director of UC Berkeley’s Center for Global Public Health, and Dr. Angel Balmaseda, director of the National Virology Laboratory in Nicaragua. One was a hospital-based study that examined children admitted to the National Pediatric Reference hospital with dengue between 2005 and 2009. The other was a prospective study that had followed 3,800 children since 2004, with blood samples collected annually.

By following dengue cases in both studies, researchers were able to identify a dramatic increase in severe dengue disease and then sequence the virus across time. They detected genetic changes in the virus that coincided with changes in disease severity, but only in the context of pre-existing immune response to specific dengue virus serotypes.

They found that children who had antibodies to dengue virus 3, which circulated in the region from 1994-1998, were at greater risk for developing severe infections when exposed to subtype 2B of dengue virus 2. They also found that children who had antibodies to dengue virus 1, which circulated from 2002-2005, were also at increased risk of severe disease from exposure to subtype 1 of dengue virus 2 after an initial period of immunity wore off.

“We showed for dengue that both the subtype of virus you get infected with and whether your body has antibodies to another type of virus matter,” said Matthew Henn, director of viral genomics at the Broad Institute. “If you get the wrong combination of the two, you are more likely to get severe disease. This study provides a framework we can utilize to eventually predict which specific virus types will proliferate in different human populations. We lacked a good model for this previously.”

The researchers followed up with tests in the lab to confirm the complex interplay of viral genetics and immune system response.

Harris understands this risk on a personal level. She has been studying dengue in Nicaragua for 24 years, and in 1995, became infected with dengue virus type 3. That puts her at greater risk for a severe reaction should she become exposed to other dengue virus serotypes.

While no vaccine yet exists for dengue, Harris noted that the vaccines currently under development aim to immunize against all types of the virus.

“Our findings have implications for vaccine development and implementation, as the precise genetics of vaccine strains, as well as the timing and serotype sequence of infection prior to and after vaccination, play an important role in determining the outcome of infection,” she said.

Harris added that this study benefited from decades of productive collaboration between U.S. and Nicaraguan researchers. “It was the multi-disciplinary approach we took to analyzing two high-quality studies that allowed us to untangle this very complex phenomenon,” she said.

Funding from the National Institute of General Medical Sciences, the National Institute of Allergy and Infectious Diseases and the Pediatric Dengue Vaccine Initiative provided support for this research.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided byUniversity of California – Berkeley. The original article was written by Sarah Yang.

Journal Reference:

M. OhAinle, A. Balmaseda, A. R. Macalalad, Y. Tellez, M. C. Zody, S. Saborio, A. Nunez, N. J. Lennon, B. W. Birren, A. Gordon, M. R. Henn, E. Harris. Dynamics of Dengue Disease Severity Determined by the Interplay Between Viral Genetics and Serotype-Specific Immunity.Science Translational Medicine, 2011; 3 (114): 114ra128 DOI: 10.1126/scitranslmed.3003084

Fluorescent rabies virus tracks how experience alters neural circuits

January 7, 2012 1 comment

A technique called monosynaptic tracing reveals how experience remodels olfactory bulb microcircuitry

Computer reconstructions showing microcircuits with synaptic contacts onto newborn granule cells (scale bar = 15 micrometres). Image: Arenkiel et al (2011)

Contrary to an age-old dogma, the brain is not fixed and immutable. After decades of research, we now know that the brains of mammals (including humans) can produce new cells after embryonic development is ended. We also know that experience alters the connections between nerve cells in a number of ways, and it is widely believed that this process, which is referred to as synaptic plasticity, is critical for learning and memory.

The adult mammalian brain contains two discrete niches of stem cells which retain the ability to generate new neurons. In rodents, it is well established that newborn cells integrate into the existing circuitry and contribute to information processing, but exactly how is unknown. Researchers from the Baylor College of Medicine and Duke University now reveal some of the details of these processes. Using genetically engineered rabies viruses, they show how new cells form connections with older ones and how their connections are modified by sensory experience.

Benjamin Arenkiel and his colleagues used a technique called monosynaptic tracing, developed by Ed Callaway of the Salk Institute, which exploits the natural properties of the rabies virus. Rabies specifically targets cells in the peripheral nerves. Following infection at the nerve endings in the skin, the viral particles are carried along the nerve fibres into the brain, by means of the neuronal machinery that transports cellular materials back and forth.

In a technically challenging and time-consuming series of experiments, the researchers created genetically engineered mice in which small numbers of neurons born post-natally (or after birth), and all the older surrounding cells to which they have become connected, are labelled with fluoroescent protein markers.

To do so, they first created three different recombinant DNA molecules. One was a ‘reporter’ construct, containing the gene encoding the red fluorescent protein tdTomato and a short DNA sequence called a start codon, which guides the protein synthesis machinery to the beginning of the gene. The gene and start codon were separated by another short DNA sequence containing four stop codons, which block synthesis of the dtTomato reporter protein, and these stop signals were flanked by short DNA sequences called loxP sites.

The second was a plasmid, or circular molecule, containing the gene encoding the rabies virus coat protein, which normally envelops the viral DNA and facilitates its entry into host cells, the gene for receptor that the virus binds to in order to gain entry into cells, and the Cre gene, encoding an enzyme which recognizes pairs of short DNA sequences called loxP sites, cuts out the intervening DNA sequences then splices the loxP sequences back together.

The third construct contained a modified rabies virus DNA sequence in which the coat protein gene was replaced with the gene encoding enhanced green fluorescent protein (EGFP).

Next, the researchers injected the reporter construct into stem cells derived from 14-day-old mouse embryos, selected the ones that had integrated the construct into their chromosomes, and implanted them into surrogate mothers’ wombs to generate a strain of mice expressing the inactive reporter gene.

As soon as the animals were born, they were anaesthetized and the plasmid was injected into the lateral ventricles, whose walls contain stem cells that produce immature neurons which migrate long distances into the olfactory bulb. An electrical field was then applied across the animals’ heads, just behind the eyes, making the nerve cell membranes more permeable. Thus, many of the neurons destined for the olfactory bulb took up the plasmid DNA containing the Cre gene, which activates the red fluorescent dtTomato reporter gene.

The animals were then returned to their cages and reared with their mothers. Half of them were housed in special cages fitted with an automated robotic system that dispensed dozens of different odours. One month later, the researchers injected the rabies virus-GFP construct into the olfactory bulb. After another week, they dissected out the bulbs, sliced and examined them under the microscope.

The fluorescent virus targets the neurons which took up the plasmid, only they express the cell surface receptor which it recognizes, but it only enters a very small number of them, making them fluoresce over the red background of the dtTomato reporter, so that they appear yellow. Infected cells express the coat protein from the plasmid, so they synthesize “live” viruses that are transported towards the synapses and then jump across them, making the cells on the other side glow bright green. But their coat protein gene is missing, so the viruses cannot jump across any more synapses.

This clever experimental design enabled the researchers to visualize some of the microcircuits within the olfactory bulbs, and to identify individual granule cells, as well as all the cells forming connections with them, in each circuit. Their analyses reveal hitherto unknown details about how the various cell types are arranged in the bulb, showing that granule cells receive numerous inhibitory connections from a poorly understood population of cells with short axons.

They also show how newborn neurons are integrated into the circuits, and how an enriched sensory environment modifies their connections. Comparison of the olfactory bulbs from animals reared with and without exposure to smells revealed that exposure to smells dramatically increased the number of synaptic inputs onto the newly-integrated granule cells (above left and right, respectively).

The classic experiments of David Hubel and Torsten Weisel showed that the visual system is critically dependent upon sensory stimulation for proper development, and this new study shows that the same is also true of neurons that are born after the developmental period.

Monosynaptic tracing is one of several advanced techniques that have been developed in recent years to investigate neuronal circuits and systems. Another is optogenetics, in which specified cell types are made to express algal proteins that render them sensitive to light, so that they can be switched on or off with great accuracy using laser light pulses delivered through fibre optic cables.

Such techniques have already enabled researchers to examine brain circuits in unprecedented detail. They will continue to do so in the years to come, allowing for the dissection of circuitry in ever greater detail as they become more advanced. This is the first time monosynaptic tracing has been used to investigate how new cells integrate into existing circuitry. A better understanding of the process could be useful for the development of neural stem cell-based transplantation therapies for neurological disorders.


Arenkiel, B., et al. (2011). Activity-Induced Remodeling of Olfactory Bulb Microcircuits Revealed by Monosynaptic Tracing. PLoS ONE6(12) DOI: 10.1371/journal.pone.0029423

Wickersham, I. R., et al. (2007). Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons. Neuron53: 639-647. DOI: 10.1016/j.neuron.2007.01.033

2011 in review

The stats helper monkeys prepared a 2011 annual report for this blog. Here’s an excerpt:

A San Francisco cable car holds 60 people. This blog was viewed about 3,300 times in 2011. If it were a cable car, it would take about 55 trips to carry that many people.

Click here to see the complete report.